Technical Analysis for GNTA - Genenta Science S.p.A.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Spinning Top | Other | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | -0.55% | |
| Bollinger Band Squeeze | Range Contraction | -0.55% | |
| Narrow Range Bar | Range Contraction | -0.55% | |
| BB Squeeze Started | Range Contraction | -0.55% |
| Alert | Time |
|---|---|
| 2x Volume Pace | about 9 hours ago |
| 1.5x Volume Pace | about 9 hours ago |
| 3x Volume Pace | about 9 hours ago |
| Fell Below Lower Bollinger Band | about 9 hours ago |
| Fell Below Previous Day's Low | about 9 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
Genenta is a clinical-stage biotechnology company pioneering the development of a proprietary hematopoietic stem cell gene therapy for the treatment of a variety of solid tumor cancers. Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells (HSPCs) to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages (Tie2 Expressing Monocytes - TEMs). TemferonTM, which is under investigation in a Phase 1/2a clinical trial in newly diagnosed Glioblastoma Multiforme patients who have an unmethylated MGMT gene promoter (uMGMT-GBM), is based on our platform technology which is not restricted to pre-selected tumor antigens nor type and may reach solid tumors, one of the main unresolved challenges in immuno-oncology.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Solid Tumors Oncology Cancer Immunotherapy Gene Therapy Cell Biology Glioblastoma Platform Technology Brain Tumor Solid Tumor Cancers Glioblastoma Multiforme
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Solid Tumors Oncology Cancer Immunotherapy Gene Therapy Cell Biology Glioblastoma Platform Technology Brain Tumor Solid Tumor Cancers Glioblastoma Multiforme
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.39 |
| 52 Week Low | 2.2 |
| Average Volume | 4,471 |
| 200-Day Moving Average | 4.30 |
| 50-Day Moving Average | 3.27 |
| 20-Day Moving Average | 3.22 |
| 10-Day Moving Average | 3.21 |
| Average True Range | 0.14 |
| RSI (14) | 43.82 |
| ADX | 9.86 |
| +DI | 24.74 |
| -DI | 32.23 |
| Chandelier Exit (Long, 3 ATRs) | 3.07 |
| Chandelier Exit (Short, 3 ATRs) | 3.49 |
| Upper Bollinger Bands | 3.39 |
| Lower Bollinger Band | 3.06 |
| Percent B (%b) | 0.08 |
| BandWidth | 10.24 |
| MACD Line | -0.04 |
| MACD Signal Line | -0.03 |
| MACD Histogram | -0.0116 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.17 | ||||
| Resistance 3 (R3) | 3.18 | 3.15 | 3.16 | ||
| Resistance 2 (R2) | 3.15 | 3.12 | 3.15 | 3.15 | |
| Resistance 1 (R1) | 3.12 | 3.11 | 3.10 | 3.11 | 3.15 |
| Pivot Point | 3.09 | 3.09 | 3.08 | 3.09 | 3.09 |
| Support 1 (S1) | 3.06 | 3.06 | 3.04 | 3.05 | 3.02 |
| Support 2 (S2) | 3.03 | 3.05 | 3.03 | 3.01 | |
| Support 3 (S3) | 3.00 | 3.03 | 3.01 | ||
| Support 4 (S4) | 2.99 |
